{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:44:59Z","timestamp":1792658699049,"version":"4.5.0"},"reference-count":19,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2014,3,29]],"date-time":"2014-03-29T00:00:00Z","timestamp":1396051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100007212","name":"Region V\u00e4stra G\u00f6taland","doi-asserted-by":"crossref","award":["ALF74100"],"award-info":[{"award-number":["ALF74100"]}],"id":[{"id":"10.13039\/100007212","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007212","name":"Region V\u00e4stra G\u00f6taland","doi-asserted-by":"crossref","award":["ALF70150"],"award-info":[{"award-number":["ALF70150"]}],"id":[{"id":"10.13039\/100007212","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background and purpose<\/jats:title>\n                    <jats:p>\n                      The treatment recommendation for\n                      <jats:styled-content style=\"fixed-case\">L<\/jats:styled-content>\n                      yme neuroborreliosis with central nervous system (\n                      <jats:styled-content style=\"fixed-case\">CNS<\/jats:styled-content>\n                      ) symptoms is intravenous ceftriaxone, according to current\n                      <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>\n                      merican and\n                      <jats:styled-content style=\"fixed-case\">E<\/jats:styled-content>\n                      uropean guidelines. For\n                      <jats:styled-content style=\"fixed-case\">L<\/jats:styled-content>\n                      yme neuroborreliosis with peripheral nervous system (\n                      <jats:styled-content style=\"fixed-case\">PNS<\/jats:styled-content>\n                      ) symptoms, treatment with intravenous ceftriaxone and oral doxycycline is considered equally effective. The purpose of this study was to evaluate the efficacy of oral doxycycline in the treatment of\n                      <jats:styled-content style=\"fixed-case\">L<\/jats:styled-content>\n                      yme neuroborreliosis with\n                      <jats:styled-content style=\"fixed-case\">CNS<\/jats:styled-content>\n                      symptoms.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients with\n                      <jats:styled-content style=\"fixed-case\">L<\/jats:styled-content>\n                      yme neuroborreliosis who had undergone cerebrospinal fluid (\n                      <jats:styled-content style=\"fixed-case\">CSF<\/jats:styled-content>\n                      ) sampling before and after treatment at the\n                      <jats:styled-content style=\"fixed-case\">D<\/jats:styled-content>\n                      epartment of\n                      <jats:styled-content style=\"fixed-case\">I<\/jats:styled-content>\n                      nfectious\n                      <jats:styled-content style=\"fixed-case\">D<\/jats:styled-content>\n                      iseases,\n                      <jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>\n                      ahlgrenska\n                      <jats:styled-content style=\"fixed-case\">U<\/jats:styled-content>\n                      niversity\n                      <jats:styled-content style=\"fixed-case\">H<\/jats:styled-content>\n                      ospital, during the period 1990\u20132012, were included in this retrospective study. The\n                      <jats:styled-content style=\"fixed-case\">CSF<\/jats:styled-content>\n                      mononuclear cell count was used as a surrogate marker of treatment outcome. Comparisons of\n                      <jats:styled-content style=\"fixed-case\">CSF<\/jats:styled-content>\n                      mononuclear cell counts were made between patients with\n                      <jats:styled-content style=\"fixed-case\">CNS<\/jats:styled-content>\n                      symptoms and patients with\n                      <jats:styled-content style=\"fixed-case\">PNS<\/jats:styled-content>\n                      symptoms before and after treatment with oral doxycycline.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty\u2010six patients classified as having\n                      <jats:styled-content style=\"fixed-case\">CNS<\/jats:styled-content>\n                      symptoms and 115 patients classified as having\n                      <jats:styled-content style=\"fixed-case\">PNS<\/jats:styled-content>\n                      symptoms were included. The decline in\n                      <jats:styled-content style=\"fixed-case\">CSF<\/jats:styled-content>\n                      mononuclear cell counts did not differ significantly between the two groups of patients. All patients with\n                      <jats:styled-content style=\"fixed-case\">CNS<\/jats:styled-content>\n                      disease showed a marked clinical improvement after treatment, even though 62% had remaining symptoms at the end of follow\u2010up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Treatment with oral doxycycline resulted in a similar decrease in\n                      <jats:styled-content style=\"fixed-case\">CSF<\/jats:styled-content>\n                      mononuclear cell counts in patients with\n                      <jats:styled-content style=\"fixed-case\">L<\/jats:styled-content>\n                      yme neuroborreliosis with\n                      <jats:styled-content style=\"fixed-case\">CNS<\/jats:styled-content>\n                      symptoms compared with patients with\n                      <jats:styled-content style=\"fixed-case\">L<\/jats:styled-content>\n                      yme neuroborreliosis with\n                      <jats:styled-content style=\"fixed-case\">PNS<\/jats:styled-content>\n                      symptoms. The results indicate that oral doxycycline is an effective treatment for\n                      <jats:styled-content style=\"fixed-case\">L<\/jats:styled-content>\n                      yme neuroborreliosis irrespective of the severity of symptoms.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ene.12420","type":"journal-article","created":{"date-parts":[[2014,3,29]],"date-time":"2014-03-29T09:36:36Z","timestamp":1396085796000},"page":"1162-1167","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Oral doxycycline for Lyme neuroborreliosis with symptoms of encephalitis, myelitis, vasculitis or intracranial hypertension"],"prefix":"10.1111","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6137-911X","authenticated-orcid":false,"given":"D.","family":"Bremell","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases Institute of Biomedicine Sahlgrenska Academy at the University of Gothenburg G\u00f6teborg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Dotevall","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Institute of Biomedicine Sahlgrenska Academy at the University of Gothenburg G\u00f6teborg Sweden"},{"name":"Department of Communicable Disease Control V\u00e4stra G\u00f6taland Region G\u00f6teborg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,3,29]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2009.02862.x"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.2217\/fnl.10.89"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2009.11.016"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004150050216"},{"key":"e_1_2_8_6_1","first-page":"553","article-title":"[Clinical courses of acute and chronic neuroborreliosis following treatment with ceftriaxone]","volume":"75","author":"Kaiser R","year":"2004","journal-title":"Nervenarzt"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2010.03175.x"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/115.2.399"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.60.6.849"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365540510027228"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70119-4"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit458"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365540110080421"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0404.2002.01358.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2009.02756.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000265517.66976.28"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1086\/508667"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.7.1078"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-8994(97)00215-4"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000029570.69134.1B"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fene.12420","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.12420","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T09:07:55Z","timestamp":1695460075000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.12420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,29]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.1111\/ene.12420"],"URL":"https:\/\/doi.org\/10.1111\/ene.12420","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,29]]},"assertion":[{"value":"2014-01-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-02-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-03-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}